Review

anti human e selectin ab (R&D Systems)

R&D Systems is a verified supplier

R&D Systems manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

R&D Systems anti human e selectin ab

(A) Representative images of adhesion assay using Calcein-AM stained CA19-9 negative (top) and positive (bottom) cells adhered to HUVECs. Scale bars = 100 μm. (B) Quantification of adhered CA19-9 neg and CA19-9 pos FC1199 (left), KPCY (middle) and FC1245 (right) cells per field. (C, D) Quantification of adhered CA19-9 pos FC1199 cells treated with anti-CA19-9 antibody (5B1; αCA19-9) (C) and anti-human <t>E-selectin</t> antibody <t>(BBA16;</t> αSELE) (D) compared with isotype control (ISO). (E, F) Quantification of adhered hM19a 2D cells treated with anti-CA19-9 antibody (5B1; αCA19-9) (E) and anti-human E-selectin antibody (BBA16; αSELE) (F) compared with isotype control (ISO). (G) Quantification of adhered Capan-2 cells after FUT3 knockout (sgFUT3) compared with a negative control (sgCtrl). *Data are presented as mean ± SD. Data are representative of at least two independent experiments. Statistical significance was determined by unpaired two-tailed t-test with Welch’s correction. *P < 0.05; **P < 0.01; ***P < 0.001.

Anti Human E Selectin Ab, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 46 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+human+e+selectin+antibody/Human+E-Selectin%2FCD62E+Antibody/bio_rxiv__64898__2026__04__08__717301-188-12-15
Average 93 stars, based on 46 article reviews

anti human e selectin ab - by Bioz Stars, 2026-09

93/100 stars

Images

1) Product Images from "CA19-9 promotes liver metastasis of pancreatic cancer through E-selectin mediated extravasation"

Article Title: CA19-9 promotes liver metastasis of pancreatic cancer through E-selectin mediated extravasation

Journal: bioRxiv

doi: 10.64898/2026.04.08.717301

Figure Legend Snippet: (A) Representative images of adhesion assay using Calcein-AM stained CA19-9 negative (top) and positive (bottom) cells adhered to HUVECs. Scale bars = 100 μm. (B) Quantification of adhered CA19-9 neg and CA19-9 pos FC1199 (left), KPCY (middle) and FC1245 (right) cells per field. (C, D) Quantification of adhered CA19-9 pos FC1199 cells treated with anti-CA19-9 antibody (5B1; αCA19-9) (C) and anti-human E-selectin antibody (BBA16; αSELE) (D) compared with isotype control (ISO). (E, F) Quantification of adhered hM19a 2D cells treated with anti-CA19-9 antibody (5B1; αCA19-9) (E) and anti-human E-selectin antibody (BBA16; αSELE) (F) compared with isotype control (ISO). (G) Quantification of adhered Capan-2 cells after FUT3 knockout (sgFUT3) compared with a negative control (sgCtrl). *Data are presented as mean ± SD. Data are representative of at least two independent experiments. Statistical significance was determined by unpaired two-tailed t-test with Welch’s correction. *P < 0.05; **P < 0.01; ***P < 0.001.

Techniques Used: Cell Adhesion Assay, Staining, Control, Knock-Out, Negative Control, Two Tailed Test

(A) Schema of study design for metastatic seeding analysis in (B, C). (B) Representative YFP IHC of liver sections one day after splenic injection of CA19-9 neg or CA19-9 pos KPCY cells. Scale bar = 200 μm. (C) Quantification of YFP+ tumor cells in liver sections of WT mice injected with CA19-9 neg or CA19-9 pos KPCY cells, normalized by tissue area (mm²). (D) Schema of study design in (E-H). (E) Representative macroscopic images of livers isolated from WT (left) and E-selectin KO (right) mice injected with CA19-9 pos cells. Scale bar = 1 cm. (F, G) Quantification of liver weight (F) and of liver weight normalized by body weight (G). (H) Quantification of CK19 positive area (%) across the whole liver sections. (I) Schema of study design in (J) (J) Quantification of YFP+ tumor cells in liver sections of WT and E-selectin KO mice injected with CA19-9 pos KPCY cells, normalized by tissue area (mm²). (K) Schema of study design in (L, M) (L, M) Quantification of CA19-9 pos KPCY cells in liver sections of WT mice injected with CA19-9 pos KPCY cells and treated with isotype control or anti-CA19-9 antibody (5B1; αCA19-9) (L), or isotype control or anti-mouse E-selectin antibody (9A9; αSele) (M), normalized by tissue area (mm²). *Data are presented as mean ± SD. Each dot represents an individual mouse. For A-H, mice were injected with 1 × 10 5 tumor cells per mouse. For I-M, mice were injected with 3 × 10 5 tumor cells per mouse. Statistical significance was calculated using unpaired two-tailed t-test with Welch’s correction. *P < 0.05; **P < 0.01; ***P < 0.001.

Figure Legend Snippet: (A) Schema of study design for metastatic seeding analysis in (B, C). (B) Representative YFP IHC of liver sections one day after splenic injection of CA19-9 neg or CA19-9 pos KPCY cells. Scale bar = 200 μm. (C) Quantification of YFP+ tumor cells in liver sections of WT mice injected with CA19-9 neg or CA19-9 pos KPCY cells, normalized by tissue area (mm²). (D) Schema of study design in (E-H). (E) Representative macroscopic images of livers isolated from WT (left) and E-selectin KO (right) mice injected with CA19-9 pos cells. Scale bar = 1 cm. (F, G) Quantification of liver weight (F) and of liver weight normalized by body weight (G). (H) Quantification of CK19 positive area (%) across the whole liver sections. (I) Schema of study design in (J) (J) Quantification of YFP+ tumor cells in liver sections of WT and E-selectin KO mice injected with CA19-9 pos KPCY cells, normalized by tissue area (mm²). (K) Schema of study design in (L, M) (L, M) Quantification of CA19-9 pos KPCY cells in liver sections of WT mice injected with CA19-9 pos KPCY cells and treated with isotype control or anti-CA19-9 antibody (5B1; αCA19-9) (L), or isotype control or anti-mouse E-selectin antibody (9A9; αSele) (M), normalized by tissue area (mm²). *Data are presented as mean ± SD. Each dot represents an individual mouse. For A-H, mice were injected with 1 × 10 5 tumor cells per mouse. For I-M, mice were injected with 3 × 10 5 tumor cells per mouse. Statistical significance was calculated using unpaired two-tailed t-test with Welch’s correction. *P < 0.05; **P < 0.01; ***P < 0.001.

Techniques Used: Injection, Isolation, Control, Two Tailed Test

Cell Culture:

Article Title: Rapid Prototyping of Arrayed Microfluidic Systems in Polystyrene for Cell-Based Assays
Article Snippet: Human umbilical vein endothelial cells (HUVECs) were cultured in EBM-2medium containing SingleQuots (Lonza,Allendale, NJ), and seeded into the microchannels at 3000 cells/μL. .. HUVECs were then cultured to confluence over 48 h and treated with 10 ng/mL interleukin 1β (IL-1β) for 4 h to induce E-selectin upregulation.45 After 4 h, HUVECs were fixed, permeabilized, and immunostained with monoclonal anti-human E-selectin antibody (R&D Systems Inc., Minneapolis, MN) and Hoechst 33342 nuclear dye (H1399, Invitrogen, Carlsbad, CA). .. Images of the culture were acquired on a Nikon Eclipse Ti inverted fluorescence microscope (Nikon Instruments, Melville, NY).

Incubation:

Article Title: Preparation of E-selectin-targeting nanoparticles and preliminary in vitro evaluation.
Article Snippet: Targeted delivery aims to concentrate therapeutic agents at their site of action and thereby enhance treatment and limit side-effects.. E-selectin on endothelial cells is markedly up-regulated by cytokine stimulation of inflamed and some tumoral tissues, promoting the adhesion of leukocytes and metastatic tumor cells, thus making it an interesting molecular target for drug delivery systems.. We report here the preparation of targeted nanoparticles from original amphiphilic block copolymers functionalized with an analog of sialyl Lewis X (SLEx), the physiological ligand of E-selectin.

Article Title: TWEAK/Fn14 pathway modulates properties of a human microvascular endothelial cell model of blood brain barrier
Article Snippet: After trypsination, differentiated unstimulated or TWEAK-stimulated hCMEC/D3 cells were pre-incubated on ice for 20 min with a solution containing PBS, 1% FCS, 0.02% sodium azide, and 25% purified human serum Immunoglobulin G(Sigma Aldrich) to inhibit binding to Fc receptors. .. After washes with a solution containing PBS, 1% FCS, and 0.02% sodium azide, cells were incubated on ice for 20 min with fluorescein-conjugated anti-human ICAM-1 antibody, fluorescein-conjugated anti-human E-selectin antibody (both from R&D Systems, Minneapolis, USA), or anti-human Fn14 phycoerythrin-conjugated antibody (eBioscience, Paris, France). ..

Article Title: Comparison of inflammation, arterial stiffness and traditional cardiovascular risk factors between rheumatoid arthritis and inflammatory bowel disease
Article Snippet: .. 100 μL aliquot was incubated with 10 μL of FITC-labelled anti-human E-selectin antibody (clone: BBIG-E5, R & D Systems) or a corresponding mouse IgG isotype (R & D Systems) at room temperature for 20 min with gentle shaking. .. At the end of incubation, 300 μL of double filtered 0.2% FBS/PBS (filtered through a 0.2 μm and then a 0.1 μm membrane filter) was added and samples were counted with a Canto II flow cytometer (BD Biosciences) for 5 min. Megamix beads (Biocytex, France), a mixture of 0.5 μm, 0.9 μm, and 3 μm beads, were used for size calibration according to the manufacture’s instruction.

Article Title: Shear Stress Modulation of IL-1β-Induced E-Selectin Expression in Human Endothelial Cells
Article Snippet: .. Cells were washed twice with DPBS ++ and incubated with 0.2 mg ml −1 fluorescein-conjugated monoclonal anti-human E-selectin antibody (BBIG-E5 clone, R&D Systems, Minneapolis, MN) at 4°C for at least 1 hr to label surface-expressed protein only – no cell permeabilizing agent was used. ..

Article Title: Shear stress modulation of IL-1β-induced E-selectin expression in human endothelial cells.
Article Snippet: .. Cells were washed twice with DPBS++ and incubated with 0.2 mg ml21 fluoresceinconjugated monoclonal anti-human E-selectin antibody (BBIGE5 clone, R&D Systems, Minneapolis, MN) at 4uC for at least 1 hr to label surface-expressed protein only – no cell permeabilizing agent was used. ..

Gentle:

Image Search Results

Journal: bioRxiv

Article Title: CA19-9 promotes liver metastasis of pancreatic cancer through E-selectin mediated extravasation

doi: 10.64898/2026.04.08.717301

Figure Lengend Snippet: (A) Representative images of adhesion assay using Calcein-AM stained CA19-9 negative (top) and positive (bottom) cells adhered to HUVECs. Scale bars = 100 μm. (B) Quantification of adhered CA19-9 neg and CA19-9 pos FC1199 (left), KPCY (middle) and FC1245 (right) cells per field. (C, D) Quantification of adhered CA19-9 pos FC1199 cells treated with anti-CA19-9 antibody (5B1; αCA19-9) (C) and anti-human E-selectin antibody (BBA16; αSELE) (D) compared with isotype control (ISO). (E, F) Quantification of adhered hM19a 2D cells treated with anti-CA19-9 antibody (5B1; αCA19-9) (E) and anti-human E-selectin antibody (BBA16; αSELE) (F) compared with isotype control (ISO). (G) Quantification of adhered Capan-2 cells after FUT3 knockout (sgFUT3) compared with a negative control (sgCtrl). *Data are presented as mean ± SD. Data are representative of at least two independent experiments. Statistical significance was determined by unpaired two-tailed t-test with Welch’s correction. *P < 0.05; **P < 0.01; ***P < 0.001.

Article Snippet: Alternatively, HUVECs were incubated with mouse IgG (Leinco Technologies, Inc., I-536) or anti-human E-selectin Ab (R&D Systems, BBA16) at 25 μg/mL for 30 minutes at 37°C.

Techniques: Cell Adhesion Assay, Staining, Control, Knock-Out, Negative Control, Two Tailed Test

Journal: bioRxiv

Article Title: CA19-9 promotes liver metastasis of pancreatic cancer through E-selectin mediated extravasation

doi: 10.64898/2026.04.08.717301

Figure Lengend Snippet: (A) Schema of study design for metastatic seeding analysis in (B, C). (B) Representative YFP IHC of liver sections one day after splenic injection of CA19-9 neg or CA19-9 pos KPCY cells. Scale bar = 200 μm. (C) Quantification of YFP+ tumor cells in liver sections of WT mice injected with CA19-9 neg or CA19-9 pos KPCY cells, normalized by tissue area (mm²). (D) Schema of study design in (E-H). (E) Representative macroscopic images of livers isolated from WT (left) and E-selectin KO (right) mice injected with CA19-9 pos cells. Scale bar = 1 cm. (F, G) Quantification of liver weight (F) and of liver weight normalized by body weight (G). (H) Quantification of CK19 positive area (%) across the whole liver sections. (I) Schema of study design in (J) (J) Quantification of YFP+ tumor cells in liver sections of WT and E-selectin KO mice injected with CA19-9 pos KPCY cells, normalized by tissue area (mm²). (K) Schema of study design in (L, M) (L, M) Quantification of CA19-9 pos KPCY cells in liver sections of WT mice injected with CA19-9 pos KPCY cells and treated with isotype control or anti-CA19-9 antibody (5B1; αCA19-9) (L), or isotype control or anti-mouse E-selectin antibody (9A9; αSele) (M), normalized by tissue area (mm²). *Data are presented as mean ± SD. Each dot represents an individual mouse. For A-H, mice were injected with 1 × 10 5 tumor cells per mouse. For I-M, mice were injected with 3 × 10 5 tumor cells per mouse. Statistical significance was calculated using unpaired two-tailed t-test with Welch’s correction. *P < 0.05; **P < 0.01; ***P < 0.001.

Article Snippet: Alternatively, HUVECs were incubated with mouse IgG (Leinco Technologies, Inc., I-536) or anti-human E-selectin Ab (R&D Systems, BBA16) at 25 μg/mL for 30 minutes at 37°C.

Techniques: Injection, Isolation, Control, Two Tailed Test

Prothrombotic effects of STEC-HUS serum are dependent on WPB exocytosis from endothelial cells. P-selectin (A) and vWF (B) expression on unstimulated HMEC-1 exposed to serum from patients with acute STEC-HUS (n = 5 for P-selectin experiments; n = 6 for vWF experiments), in the presence or in the absence of different complement inhibitors (sCR1, 150 µg/mL; factor B inhibitor, iptacopan,10 µM; eculizumab 100 µg/mL) or to a pool of control sera (normal human serum, NHS), run in parallel. Results are shown as pixel 2 /high-power field (HPF) of stained surface area. Data are mean ± SD. Circles represent single patients’ data. The addition of either sCR1, or iptacopan or eculizumab to patient’s serum significantly decrease both P-selectin and vWF expression induced by patient’s serum alone. *P < 0.05 vs STEC-HUS serum alone (ANOVA, followed by Tukey’s multiple comparisons test for data of P-selectin expression and by Holm-Šídák’s multiple comparisons test for data of vWF expression). (C) Endothelial surface area covered by thrombi on ADP-activated HMEC-1 exposed to serum from STEC-HUS patients collected during the acute phase of the disease and then perfused with whole blood. Before the experiments, HMEC-1 were left for 16 hours with medium added or not with the RalA inhibitor BQU57 (10 µM). Data are expressed as mean ± SD of percentages of serum-induced thrombus formation in respect to a pool of control sera (normal human serum, NHS), run in parallel in each experiment and set as 100% (n = 3 independent experiments). Circles indicate single patients’ data. Horizontal dashed lines indicate upper and lower limits of the normal range . *P < 0.05 (paired Student’s t test). (D) Representative confocal microscopy images (original magnification X200) of experiments of thrombus formation (green staining) relative to <xref ref-type=

Figure 6C . Scale bar: 100 µm. " width="100%" height="100%">

Journal: Frontiers in Immunology

Article Title: Molecular determinants of STEC-HUS: from complement activation to microvascular thrombosis

doi: 10.3389/fimmu.2026.1749811

Figure Lengend Snippet: Prothrombotic effects of STEC-HUS serum are dependent on WPB exocytosis from endothelial cells. P-selectin (A) and vWF (B) expression on unstimulated HMEC-1 exposed to serum from patients with acute STEC-HUS (n = 5 for P-selectin experiments; n = 6 for vWF experiments), in the presence or in the absence of different complement inhibitors (sCR1, 150 µg/mL; factor B inhibitor, iptacopan,10 µM; eculizumab 100 µg/mL) or to a pool of control sera (normal human serum, NHS), run in parallel. Results are shown as pixel 2 /high-power field (HPF) of stained surface area. Data are mean ± SD. Circles represent single patients’ data. The addition of either sCR1, or iptacopan or eculizumab to patient’s serum significantly decrease both P-selectin and vWF expression induced by patient’s serum alone. *P < 0.05 vs STEC-HUS serum alone (ANOVA, followed by Tukey’s multiple comparisons test for data of P-selectin expression and by Holm-Šídák’s multiple comparisons test for data of vWF expression). (C) Endothelial surface area covered by thrombi on ADP-activated HMEC-1 exposed to serum from STEC-HUS patients collected during the acute phase of the disease and then perfused with whole blood. Before the experiments, HMEC-1 were left for 16 hours with medium added or not with the RalA inhibitor BQU57 (10 µM). Data are expressed as mean ± SD of percentages of serum-induced thrombus formation in respect to a pool of control sera (normal human serum, NHS), run in parallel in each experiment and set as 100% (n = 3 independent experiments). Circles indicate single patients’ data. Horizontal dashed lines indicate upper and lower limits of the normal range . *P < 0.05 (paired Student’s t test). (D) Representative confocal microscopy images (original magnification X200) of experiments of thrombus formation (green staining) relative to Figure 6C . Scale bar: 100 µm.

Article Snippet: Cells were washed again and treated with the following specific antibodies: FITC-conjugated rabbit anti-human C3c-complement (Dako, that recognizes C3c, part of C3 and C3b, 1:300 final dilution in Dapi 1 μg/mL); or rabbit anti-human complement C5b-9 complex (Calbiochem, 1:200 final dilution in PBS1X) followed by FITC-conjugated secondary antibody (Jackson ImmunoResearch Laboratories, 1:50 final dilution in 1 μg/mL Dapi); or goat anti-human C4 (Abcam, 1:100 final dilution in PBS1X) followed by Cy3-conjugated secondary antibody (Jackson ImmunoResearch Laboratories, 1:200 final dilution in Dapi 1 μg/mL); or FITC-conjugated anti-human IgG (Sigma Aldrich, 1:32 final dilution in 1 μg/mL Dapi); or mouse anti-human P-selectin (R&D System, 20 μg/mL final concentration in PBS1X), followed by Cy3-conjugated secondary antibody (Jackson ImmunoResearch Laboratories, 1:60 final dilution in 1 μg/mL Dapi); or rabbit anti-human vWF (Dako, 10 μg/mL final concentration in PBS1X), followed by Cy3-conjugated secondary antibody (Jackson ImmunoResearch Laboratories, 1:50 final dilution in 1 μg/mL Dapi).

Techniques: Expressing, Control, Staining, Confocal Microscopy

( A – C ): P-selectin expression on unstimulated ( A ), ADP-stimulated ( B ), and TRAP-stimulated ( C ) platelets of patients with sepsis and septic shock compared to healthy controls at T0, T1, and T2. Results are expressed as a % of P-selectin-positive platelets, identified as CD42 B-positive events. ( A ) T0 vs. CTRL: p bonf = 0.0006; T1 vs. CTRL: p bonf = 0.0006; T2 vs. CTRL: p bonf = 0.12; ( B ) T0 vs. CTRL: p bonf = 0.026; T1 vs. CTRL: p bonf = 0.056; T2 vs. CTRL: p bonf = 0.037; ( C ) n.s.= not significant. Bonferroni correction was applied for all pairwise comparisons; p -values (p bonf ) are reported. Sample size: n = 10 at T0 and T2, n = 9 at T1. * p < 0.05, ** p < 0.005. ns = no significance.

Journal: Pathogens

Article Title: Early Platelet Dysfunction in Sepsis: An ICU Pilot Study

doi: 10.3390/pathogens15020196

Figure Lengend Snippet: ( A – C ): P-selectin expression on unstimulated ( A ), ADP-stimulated ( B ), and TRAP-stimulated ( C ) platelets of patients with sepsis and septic shock compared to healthy controls at T0, T1, and T2. Results are expressed as a % of P-selectin-positive platelets, identified as CD42 B-positive events. ( A ) T0 vs. CTRL: p bonf = 0.0006; T1 vs. CTRL: p bonf = 0.0006; T2 vs. CTRL: p bonf = 0.12; ( B ) T0 vs. CTRL: p bonf = 0.026; T1 vs. CTRL: p bonf = 0.056; T2 vs. CTRL: p bonf = 0.037; ( C ) n.s.= not significant. Bonferroni correction was applied for all pairwise comparisons; p -values (p bonf ) are reported. Sample size: n = 10 at T0 and T2, n = 9 at T1. * p < 0.05, ** p < 0.005. ns = no significance.

Article Snippet: Measurement of soluble P-selectin and soluble CD40 ligand in serum was per-formed using the anti-human P-selectin (R&D System, Inc., Minneapolis, MN, USA) and human CD40L/TNFSF5 (R&D System, Inc., Minneapolis, MN, USA) immunoassay kits ac-cording to the manufacturer’s instructions.

Techniques: Expressing

( A , B ): Patient soluble CD40L ( A ) and soluble P-selectin ( B ) plasma levels at times T0, T1, and T2 compared to controls. ( A ) T0 vs. CTRL: p bonf = 0.05; T1 vs. CTRL: p bonf = 0.04; T2 vs. CTRL: p bonf = 0.018. Bonferroni correction was applied for all pairwise comparisons; p -values (p bonf ) are re-ported. Sample size: n = 10 at T0 and T2, n = 9 at T1. * p < 0.05. ns = no significance.

Journal: Pathogens

Article Title: Early Platelet Dysfunction in Sepsis: An ICU Pilot Study

doi: 10.3390/pathogens15020196

Figure Lengend Snippet: ( A , B ): Patient soluble CD40L ( A ) and soluble P-selectin ( B ) plasma levels at times T0, T1, and T2 compared to controls. ( A ) T0 vs. CTRL: p bonf = 0.05; T1 vs. CTRL: p bonf = 0.04; T2 vs. CTRL: p bonf = 0.018. Bonferroni correction was applied for all pairwise comparisons; p -values (p bonf ) are re-ported. Sample size: n = 10 at T0 and T2, n = 9 at T1. * p < 0.05. ns = no significance.

Techniques: Clinical Proteomics

EV surface marker changes after RIC treatment: The expression of the EV-markers CD62 and MCP-1 is plotted showing the Log 2 fold changes compared to the baseline sample of each patient. The p-value is shown for both the significant changes within RIC group (red) and compared with the miRNA expression changes over time in Sham group (grey). ( a ) CD62 shows an upregulation in RIC treated patients compared to Sham. ( b ) MCP-1 showed no significant changes in between the different timepoints

Journal: BMC Neuroscience

Article Title: Exploring extracellular vesicle surface markers and microRNA regulation following remote ischemic conditioning in patients with stroke; a randomized-controlled pilot study

doi: 10.1186/s12868-025-00993-1

Figure Lengend Snippet: EV surface marker changes after RIC treatment: The expression of the EV-markers CD62 and MCP-1 is plotted showing the Log 2 fold changes compared to the baseline sample of each patient. The p-value is shown for both the significant changes within RIC group (red) and compared with the miRNA expression changes over time in Sham group (grey). ( a ) CD62 shows an upregulation in RIC treated patients compared to Sham. ( b ) MCP-1 showed no significant changes in between the different timepoints

Article Snippet: CD62 E/P , R & D Systems , BBA1 , BBIG-E(13D5).

Techniques: Marker, Expressing

Correlation analysis of significant miRNA measurements (hsa-miR-19b-3p, hsa-miR-30d-5p, hsa-miR-374a-5p, hsa-miR-20a/20b-5p, hsa-miR-24-3p) and CD62/P-selectin. The histograms on the diagonal show the distribution of each variable. The lower triangular panels depict scatter plots with fitted lines, illustrating the linear relationships between pairs of variables. The upper triangular panels display the correlation coefficients, with significance levels indicated by asterisks (* p < 0.05, ** p < 0.01, *** p < 0.001)

Journal: BMC Neuroscience

Article Title: Exploring extracellular vesicle surface markers and microRNA regulation following remote ischemic conditioning in patients with stroke; a randomized-controlled pilot study

doi: 10.1186/s12868-025-00993-1

Figure Lengend Snippet: Correlation analysis of significant miRNA measurements (hsa-miR-19b-3p, hsa-miR-30d-5p, hsa-miR-374a-5p, hsa-miR-20a/20b-5p, hsa-miR-24-3p) and CD62/P-selectin. The histograms on the diagonal show the distribution of each variable. The lower triangular panels depict scatter plots with fitted lines, illustrating the linear relationships between pairs of variables. The upper triangular panels display the correlation coefficients, with significance levels indicated by asterisks (* p < 0.05, ** p < 0.01, *** p < 0.001)

Article Snippet: CD62 E/P , R & D Systems , BBA1 , BBIG-E(13D5).

Techniques:

( A and B ) dSTORM imaging and analysis showing PD-L1 localizations per square micrometer in EMT6 cells with higher concentrations of talazoparib (Tal) after 48 hours. Blue: TIRF microscopy cell membrane; red: TIRF microscopy PD-L1 and dSTORM microscopy PD-L1 representative images. Data represent mean ± SD ( N = 3). Scale bars, 10 μm. ( C ) Representative images of EMT6 3D spheroids cocultured with activated splenocytes, at a 1:100 ratio, respectively, following treatments with Tal and PD-L1i, separately or combined. Scale bars, 300 μm. ( D ) Quantification of mCherry % area. Spheroids were either untreated (UT), supplemented with splenocytes (UT + spleen), or treated with 1 μM Tal and 10 μM PD-L1i, separately or combined. Data represent mean ± SD ( N = 3, n = 10), and statistical significance was calculated using two-sided repeated-measures ANOVA ( P < 0.05). ( E and F ) Representative images and quantification of immunofluorescence staining of melanoma (E) Murine D4M.3A. Scale bars, 100 μm. (F) Patient-derived specimens. Scale bars, 10 μm. The nucleus was stained with DAPI (blue), and P-selectin was stained with Cy5-labeled antibody (SELP, cyan). Data represent mean ± SD; at least three fields were imaged from each specimen, N = 3. ( G ) P-selectin expression in BRCA-mutated EMT6 primary (left) and brain metastases (right). Nuclei are stained with DAPI in blue and P-selectin (SELP) in red. Scale bars, 100 μm.

Journal: Science Advances

Article Title: Two-in-one nanoparticle platform induces a strong therapeutic effect of targeted therapies in P-selectin–expressing cancers

doi: 10.1126/sciadv.adr4762

Figure Lengend Snippet: ( A and B ) dSTORM imaging and analysis showing PD-L1 localizations per square micrometer in EMT6 cells with higher concentrations of talazoparib (Tal) after 48 hours. Blue: TIRF microscopy cell membrane; red: TIRF microscopy PD-L1 and dSTORM microscopy PD-L1 representative images. Data represent mean ± SD ( N = 3). Scale bars, 10 μm. ( C ) Representative images of EMT6 3D spheroids cocultured with activated splenocytes, at a 1:100 ratio, respectively, following treatments with Tal and PD-L1i, separately or combined. Scale bars, 300 μm. ( D ) Quantification of mCherry % area. Spheroids were either untreated (UT), supplemented with splenocytes (UT + spleen), or treated with 1 μM Tal and 10 μM PD-L1i, separately or combined. Data represent mean ± SD ( N = 3, n = 10), and statistical significance was calculated using two-sided repeated-measures ANOVA ( P < 0.05). ( E and F ) Representative images and quantification of immunofluorescence staining of melanoma (E) Murine D4M.3A. Scale bars, 100 μm. (F) Patient-derived specimens. Scale bars, 10 μm. The nucleus was stained with DAPI (blue), and P-selectin was stained with Cy5-labeled antibody (SELP, cyan). Data represent mean ± SD; at least three fields were imaged from each specimen, N = 3. ( G ) P-selectin expression in BRCA-mutated EMT6 primary (left) and brain metastases (right). Nuclei are stained with DAPI in blue and P-selectin (SELP) in red. Scale bars, 100 μm.

Article Snippet: The slides were subsequently incubated with mouse anti-human E/P selectin (R&D, 1:30 dilution) for 1 hour, and then incubated with mouse-IgG ƙ BP-CFL 488 (catalog no. sc-516176, Santa Cruz Biotechnology, 1:20 dilution) for an additional 1 hour, followed by Hoechst fluorescent dye (1:5000) for an additional 10 min for nuclei counterstaining.

Techniques: Imaging, Microscopy, Membrane, Immunofluorescence, Staining, Derivative Assay, Labeling, Expressing

( A ) Representative images of time course internalization of Cy5-labeled NPs into D4M.3A 3D spheroids. Scale bars, 400 μm. ( B ) Time course quantification of Cy5 intensity within D4M.3A 3D spheroids. ( C ) Representative images of Cy5-labeled NPs internalization into D4M.3A 3D spheroids after 22 hours. The spheroids were preincubated with SELPi for 1 hour before NPs addition. Scale bars, 400 μm. ( D ) Representative Z-stack images of Cy5-labeled PLGA-PEG-GLY-(OSO 3 Na) 2 NPs internalization into the core of D4M.3A 3D spheroids after 24 hours, preincubated in the presence or absence of 10 μM SELPi. Scale bars, 200 μm. ( E ) Quantification of Cy5 intensity over time of nontargeted NPs and P-selectin–targeted NPs, after preincubation of the D4M.3A 3D spheroids with increasing SELPi concentrations. All quantifications are representative of three independent experiments. The data correspond to the mean ± SD of at least eight 3D spheroids per group, and statistical significance was determined using a two-way ANOVA test. ( F and G ) P-selectin binding assay of PLGA-PEG-GLY-(OSO 3 Na) 2 NPs and PLGA-PEG NPs. Plates were coated with human recombinant P-selectin (rhSELP) or with skim milk (nonspecific binding control) and then incubated with PLGA-PEG-GLY-(OSO 3 Na) 2 NPs or PLGA-PEG NPs for 15 min. (F) Fluorescence intensity of Cy5-labeled NPs after incubation with rhSELP or skim milk. (G) The fluorescence intensity ratio of rhSELP/skim milk. Bars represent mean ± SD, and a two-way ANOVA was used for statistical analysis.

Journal: Science Advances

Article Title: Two-in-one nanoparticle platform induces a strong therapeutic effect of targeted therapies in P-selectin–expressing cancers

doi: 10.1126/sciadv.adr4762

Figure Lengend Snippet: ( A ) Representative images of time course internalization of Cy5-labeled NPs into D4M.3A 3D spheroids. Scale bars, 400 μm. ( B ) Time course quantification of Cy5 intensity within D4M.3A 3D spheroids. ( C ) Representative images of Cy5-labeled NPs internalization into D4M.3A 3D spheroids after 22 hours. The spheroids were preincubated with SELPi for 1 hour before NPs addition. Scale bars, 400 μm. ( D ) Representative Z-stack images of Cy5-labeled PLGA-PEG-GLY-(OSO 3 Na) 2 NPs internalization into the core of D4M.3A 3D spheroids after 24 hours, preincubated in the presence or absence of 10 μM SELPi. Scale bars, 200 μm. ( E ) Quantification of Cy5 intensity over time of nontargeted NPs and P-selectin–targeted NPs, after preincubation of the D4M.3A 3D spheroids with increasing SELPi concentrations. All quantifications are representative of three independent experiments. The data correspond to the mean ± SD of at least eight 3D spheroids per group, and statistical significance was determined using a two-way ANOVA test. ( F and G ) P-selectin binding assay of PLGA-PEG-GLY-(OSO 3 Na) 2 NPs and PLGA-PEG NPs. Plates were coated with human recombinant P-selectin (rhSELP) or with skim milk (nonspecific binding control) and then incubated with PLGA-PEG-GLY-(OSO 3 Na) 2 NPs or PLGA-PEG NPs for 15 min. (F) Fluorescence intensity of Cy5-labeled NPs after incubation with rhSELP or skim milk. (G) The fluorescence intensity ratio of rhSELP/skim milk. Bars represent mean ± SD, and a two-way ANOVA was used for statistical analysis.

Techniques: Labeling, Binding Assay, Recombinant, Control, Incubation, Fluorescence

Review

anti human e selectin ab (R&D Systems)

Structured Review

Images

1) Product Images from "CA19-9 promotes liver metastasis of pancreatic cancer through E-selectin mediated extravasation"

Related Articles

Cell Culture:

Incubation:

Gentle:

Similar Products

Image Search Results